Clicky

Rani Therapeutics Holdings, Inc.(RANI)

Description: Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was founded in 2012 and is headquartered in San Jose, California.


Keywords: Biopharmaceutical Diabetes Organ Systems Osteoporosis Endocrine System Peptide Hormones Psoriatic Arthritis Growth Hormone Neuroendocrine Tumors Acromegaly Glucagon Treatment Of Osteoporosis Glands Growth Hormone Deficiency Parathyroid Hormone Neuroendocrinology Hypoparathyroidism Octreotide

Home Page: www.ranitherapeutics.com

RANI Technical Analysis

2051 Ringwood Avenue
San Jose, CA 95131
United States
Phone: 408 457 3700


Officers

Name Title
Mr. Mir A. Imran Exec. Chairman
Mr. Talat Imran CEO & Director
Mr. Svai S. Sanford Chief Financial Officer
Dr. Mir Hashim Chief Scientific Officer
Mr. Eric Groen Gen. Counsel
Ms. Bella Vazquez VP of HR

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.6693
Price-to-Sales TTM: 313.1706
IPO Date: 2021-07-30
Fiscal Year End: December
Full Time Employees: 114
Back to stocks